Agenda
Session 1
Moderators
Prof. Lucian Negreanu (RO)
Prof. Bogdan Mateescu (RO)
09:00 – 09:20
Introduction
Moderators
09:20 – 10:00
Aiming Higher in IBD: New Goals for Patients, New Opportunities for Care
• highlighting the current unmet needs in IBD the evolving treatment goals and ambitions for patients (STRIDE III)
• key clinical data on the latest IL-23 inhibitor
• from theory to practice – Italian experience
Prof. Gionata Fiorino (IT)
10:00- 10:10
Discussion & Q&A
Prof. Gionata Fiorino (IT)
Prof. Lucian Negreanu (RO)
Prof. Bogdan Mateescu (RO)
10:10 – 10:55
Closing the Gap in Perianal Fistulizing Disease
What are the unmet needs and evolving targets in perianal fistulizing Crohn’s disease?
• Review of current challenges in PFCD management and how treatment goals are evolving in line with new clinical expectations
What are the key findings from recent trials for perianal fistulizing Crohn’s disease?
Overview of the FUZION trial:
• Study design, demographics and main goals
• Key efficacy outcomes: Primary and secondary endpoints (FUZION Week 24) and longer-term outcomes (FUZION Week 48)
• from theory to practice – Austian experience
Prof. Alexander Moschen (AT)
Dr. Cristian Tieranu (RO)
10:55 – 11:15
Discussion & Q&A
Prof. Lucian Negreanu (RO)
Prof. Bogdan Mateescu (RO)
Prof. Alexander Moschen (AT)
Dr. Cristian Tieranu (RO)
11:15 – 11:30
Coffee break
11:30 -12:10
Tomorrow’s IBD: New Targets, New Possibilities
• Short overview of what is coming for IBD in the future (combination therapy, oral
• IL-23RA, REASON/transmural healing
• from theory to practice – German experience
Prof. Stefan Schreiber (DE)
12:10 – 12:30
Discussion & Q&A
Prof. Stefan Schreiber (DE)
Prof. Lucian Negreanu (RO)
Prof. Bogdan Mateescu (RO)
12:30-13:00
Clincal cases – Romanian experience
Prof. Lucian Negreanu (RO)
Prof. Bogdan Mateescu (RO)
13:00– 14:00
Lunch
Session 2
Moderators
Prof. Lucian Negreanu (RO)
Prof. Bogdan Mateescu (RO)
14:00 – 15:00
Workshop
15:00 -15:20
Behind the trial: from protocol to practice: what it takes to successfully run a Clinical Study at Site Level
• Translating the protocol into real clinical practice
• Patient identification, screening, recruitment and retention
• Key milestones from site initiation to study close-out
• Infrastructure, resources and operational capabilities
• What investigators should consider before taking on a study
• Assessing feasibility and understanding the commitment required
• Common challenges and practical lessons from experienced trial sites
Dr. Sorina Telescu
15:20 -15:35
Coffee break
15:35 – 16:25
Raising the Bar in IBD: The New Treatment Ambition
• an overview of the most relevant new data in Crohn’s disease
• Long-term outcomes (GALAXI 3-year)
• Outcomes following tumour necrosis factor (TNF) failure (GALAXI)
• Overview of clinical outcomes (dose-ranging and long-term), stenotic CD, and ulcer size data (GALAXI/GRAVITI)
• important new data in ulcerative colitis (UC) and explore how these findings may impact patient management.
Key clinical trial updates in UC:
• Histological outcomes over time (QUASAR)
Prof. Eugen Dumitru (RO)
16:25-16:35
Discussion & Q&A
Prof. Eugen Dumitru (RO)
Prof. Lucian Negreanu (RO)
Prof. Bogdan Mateescu (RO)
16:35 – 17:00
Conclusions and closing
Moderators
